Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases
详细信息 查看全文
- 作者：Xiaoyan Qiu ; Xiong Xiao ; Nan Li ; Yuemin Li ; lym@swu.edu.cn" class="auth_mail" title="E-mail the corresponding author
- 关键词：HAT ; histone acetyltransferases ; HSP70 ; heat shock protein 70 ; GDNF ; glial cell line-derived neurotrophic factor ; BDNF ; brain derived neurotrophic factor ; SMN ; survival motor neuron ; FMR ; fragile X mental retardation ; iNOS ; inducible nitric oxide synthase ; MMP-9 ; matrix metalloproteinase-9 ; MIP-1 ; macrophage inflammatory protein-1 ; MCP-1 ; monocyte chemoattractant protein-1 ; IGFBP-3 ; insulin-like growth factors binding protein-3 ; PCNA ; proliferating cell nuclear antigen ; FADD ; fas associated deat
- 刊名：Progress in Neuropsychopharmacology & Biological Psychiatry
- 出版年：2017
- 出版时间：4 January 2017
- 年：2017
- 卷：72
- 期：Complete
- 页码：60-72
- 全文大小：868 K
文摘
- •
Hypoacetylation which is partly mediated by histone deacetylase (HDAC), plays a causative role in the etiology of various clinical disorders.
- •
10">HDAC inhibitors (HDACis) can restore or increase the level of histone acetylation.
- •
15">HDACis as potential novel therapeutic agents could be used alone or in adjunct to other pharmacological agents in various clinical diseases.